Latest News
- Since November 1, ist Hyftor® 2 mg/g Gel im deutschen Gesundheitsmarkt als verschreibungspflichtiges Medikament verfügbar. Vertriebspartner in Deutschland ist die PHOENIX Pharma-Einkauf GmbH, Hanau. Somit ist Hyftor® 2 mg/g Gel über die Apotheken und vollsortierte Großhändler bestellbar.
For further information on the product see: Hyftor | European Medicines Agency (europa.eu) - On May 15, 2023, the European Medicines Agency, EMA, granted marketing authorisation to Plusultra pharma GmbH for the medicinal product Hyftor 2 mg/g Gel (Sirolimus), for the treatment of facial angiofibroma associated with tuberous sclerosis (TSC: Tuberous Sclerosis Complex) in adults and paediatric patients aged 6 years and older.
- On May 15, 2023, bestätigte die European Medicines Agency (EMA) den Orphan Drug Status für Hyftor® 2 mg/g Gel (Sirolimus) zur Behandlung der tuberösen Sklerose (gutartige Hauttumore im Gesicht; faziale Angiofibrome). Orphan Maintenance Assessment Report (europa.eu)
Contribute to Society by Providing Critical but Neglected Pharmaceuticals and Medical Devices.
About Plusultra pharma
As a research and development-based pharmaceutical company, we develop pharmaceuticals for unmet needs, such as orphan drugs. Before delivering new products, we always consider the needs of our customers.
Pipeline
Plusultra pharma, as a group of Nobelpharma, has earnestly addressed the launch of medicines that other companies do not pursue, in order to fulfil the needs of society.
Contact Us
“Critical but neglected – That is precisely why it must be created.”
Plusultra pharma GmbH and Plusultra pharma UK Ltd. were established in Duesseldorf, Germany, and Oxford, United Kingdom, respectively in 2020, as overseas subsidiaries in Europa regions of Nobelpharma Group. The headquarter of the group, Nobelpharma was founded in 2003 in Tokyo, Japan, to fulfill our mission of “Contributing to Society by Providing Critical but Neglected Pharmaceuticals and Medical Devices“ that other companies do not pursue. We have since obtained approvals for the manufacturing and sale of new drugs in numbers on par with large pharmaceutical companies, and we have been providing these drugs to patients. We take much pride in the unique corporate philosophy that has made this possible.